Fox_Molly

Molly W. Fox

Download IconDownload Print IconPrint
Fox_Molly

Molly W. Fox

Partner

Boston + 1 617 526 6812

Molly W. Fox is an experienced corporate attorney who counsels public and private companies and financial institutions on capital markets, corporate finance, corporate governance, and securities matters, with an emphasis on public offerings and public company representation. In addition, she advises emerging companies on venture capital financings, initial public offerings and other strategic transactions. Over the years, Ms. Fox has developed a practice representing a variety of companies in the life sciences and technology industries, as well as underwriters and venture capital funds, in domestic and international transactions. 

Learn more about Ms. Fox’s practice and how she can support your startup on WilmerHaleLaunch.com.

While attending law school, Ms. Fox worked in the London office of Freshfields Bruckhaus Deringer, where she researched various issues of US law and assisted with several initial public offerings. Prior to law school, she spent two years at Sullivan & Cromwell LLP in New York City.

Community Involvement

Ms. Fox serves on the appeals board for the Massachusetts Supplier Diversity Office, which certifies minority and women-owned businesses in the Commonwealth. She also advises several pro bono clients, including the Massachusetts Adoption Resource Exchange (MARE), which seeks to find adoptive homes for children and teens in foster care, and From the Top, a nonprofit organization dedicated to celebrating young classically-trained musicians through scholarships, arts education programs, and an acclaimed NPR radio program. Ms. Fox has previously worked with the Juvenile Rights Advocacy Project, where she represented girls in the Massachusetts juvenile justice system for legal services, including child abuse, delinquency, post-disposition administrative advocacy, and public benefits matters.

Experience

  • Ms. Fox has represented either the issuer or the underwriters in numerous IPOs, follow-on offerings and other equity and debt offerings, including the following:

    • Xilio Therapeutics in its $130 million initial public offering
    • Cue Health in its $200 million initial public offering
    • Viridian Therapeutics in its $98 million follow-on public offering
    • Rallybio in its $93 million initial public offering
    • Kymera Therapeutics in its $200 million initial public offering and $257 million follow-on public offering
    • Akouos in its $244 million initial public offering
    • Generation Bio in its $230 million initial public offering
    • IVERIC bio in its follow-on public offering of common stock and pre-funded warrants to purchase common stock
    • Arvinas in its $115 million follow-on public offering
    • Thermo Fisher Scientific in concurrent public offerings of €4.4 billion aggregate principal amount of euro-denominated notes and $900 million aggregate principal amount of USD-denominated notes
    • Akamai in its 144A offering of $1.15 billion in convertible senior notes
    • Danaher Corporation in concurrent follow-on public offerings of $1.44 billion of common stock and $1.60 billion of mandatory convertible preferred stock
    • Epizyme in numerous follow-on public offerings, including its March 2019 $172.5 million concurrent public offerings of common stock and preferred stock
    • Epizyme in its establishment of funding agreements with Royalty Pharma and its affiliate for up to $270 million, including an expandable loan facility
    • Syros Pharmaceuticals in its $70 million concurrent follow-on public offerings
    • HubSpot in its $144 million initial public offering and $167 million follow-on public offering
    • Imprivata in its $86 million initial public offering and $79 million secondary offering
    • Biotie Therapies in its $64 million initial public offering, the first U.S. IPO of a Finnish company in over more than 20 years
    • Nabriva Therapeutics in its $106 million initial public offering
    • Demandware in its $101 million initial public offering
    • TechTarget in its $115 million initial public offering and in its $36 million secondary offering
  • Ms. Fox advises public companies in the establishment of "at-the-market" sales arrangements, PIPEs, and strategic equity transactions.
  • Ms. Fox also represents private companies in various stages of development, including in venture capital and strategic financings. Recently this included representation of Generation Bio in its $110 million Series C crossover financing.

Recognition

  • Selected by peers for inclusion in Best Lawyers in America for biotechnology and life sciences practice (2024).
  • Named a Thomson Reuters Stand-out Lawyer – independently rated and selected by clients.
  • Named to Boston Magazine’s Top Lawyers list in the area of securities law (2022).

Insights & News

View all of Molly's insights & news

Credentials

  • Education

    • JD, Boston College Law School, 2006

      cum laude Articles Editor, Boston College Law Review

    • BA, Communications, Boston College, 2001

      magna cum laude

  • Admissions

    • Massachusetts

    • New York

Credentials